Pharmaceutical Italian pharma major Recordati presented four poster presentations and one product theater featuring the company’s endocrinology portfolio at the Endocrine Society’s annual meeting, ENDO 2025, taking place in San Francisco, California,
including a presentation relating to the expanded indication of Isturisa (osilodrostat) for the treatment of endogenous hypercortisolemia in patients with Cushing’s syndrome. 14 July 2025